This metabolic relationship creates nutrient-rich microenvironment and supports the breast cancer growth, especially in cases associated with obesity
Starting July 1, 2026, eligible Part D members can get Wegovy or Zepbound for a flat $50 a month through the new Medicare GLP-1 Bridge Program - here's exactly who qualifies and how our team manages the process
With clinician-led assessment, gradual dose adjustment and structured follow-up, patients can move forward safely and confidently
Clinical Monitoring Guidelines Comprehensive Safety and Efficacy Monitoring Regular monitoring ensures therapeutic efficacy while identifying potential adverse effects early in the treatment course
Wegovy has been approved by the FDA to reduce risk of major adverse cardiovascular events (MACE) in those with a history of MACE, but studies of Zepbound are still pending
Understanding what is typical can help you distinguish between expected, manageable symptoms and those that require prompt medical attention